FRESH研究:采用新型FRED X抗血栓表面涂层血流导向装置治疗颅内动脉瘤——161例患者首次多中心经验
这项回顾性多中心研究分析了9个中心连续161例颅内动脉瘤患者(184个动脉瘤,11.2%为急性破裂)使用FRED X血流导向装置的治疗情况。装置全部成功植入,主要不良事件率3.1%,血栓事件4.3%,仅2例(1.2%)导致缺血性卒中;平均随访7.0个月完全闭塞率66.0%。作者认为FRED X安全可行,血栓并发症率低,短期闭塞率满意。
要点
- FRED X在全部手术中成功植入,主要不良事件率3.1%,血栓事件率4.3%(血栓事件中仅2例、1.2%导致缺血性卒中)。
- 术后神经病学致残率和死亡率分别为1.9%和1.2%。
- 平均随访7.0个月动脉瘤完全闭塞率为66.0%。
核心结论
- 作者认为新型FRED X是治疗动脉瘤安全可行的装置;在这项回顾性多中心研究中血栓并发症率低,短期闭塞率满意。
研究设计与样本
- 回顾性分析9个国际神经血管中心连续接受FRED X治疗的颅内动脉瘤患者的病历、手术和影像资料;共161例患者(77.6%女性,平均年龄55岁)184个动脉瘤(11.2%急性破裂),77.0%位于前循环、最常见于ICA(72.7%)。
关键影像表现/征象
- FRED X在所有手术中成功植入;29.8%行额外弹簧圈栓塞,2.5%需支架内球囊血管成形术。
诊断标准与关键数值
- 主要不良事件率3.1%;血栓事件7例(4.3%),其中4例术中支架内血栓、4例术后支架内血栓(1例兼有围手术期和术后血栓);血栓事件中仅2例(1.2%)导致主要不良事件(缺血性卒中)。术后神经病学致残率1.9%、死亡率1.2%。平均随访7.0个月动脉瘤完全闭塞率66.0%。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND AND PURPOSE: Flow diverters with antithrombotic coatings are increasingly used to improve the safety of flow diverter treatments of intracranial aneurysms. This study aimed to investigate the safety and short-term efficacy of the new FRED X flow diverter.
MATERIALS AND METHODS: Medical charts and procedural and imaging data of a consecutive series of patients with intracranial aneurysms who were treated with the FRED X at 9 international neurovascular centers were retrospectively analyzed.
RESULTS: One hundred sixty-one patients (77.6% women; mean age, 55 years) with 184 aneurysms (11.2% acutely ruptured) were included in this study. Most aneurysms were located in the anterior circulation (77.0%), most frequently at the ICA (72.7%). The FRED X was successfully implanted in all procedures. Additional coiling was performed in 29.8%. In-stent balloon angioplasty was necessary in 2.5%. The rate of major adverse events was 3.1%. Thrombotic events occurred in 7 patients (4.3%) with 4 intra- and 4 postprocedural in-stent thromboses, respectively (1 patient had both peri- and postprocedural thrombosis). Of these thrombotic events, only 2 (1.2%) led to major adverse events (ischemic strokes). Postinterventional neurologic morbidity and mortality were observed in 1.9% and 1.2%, respectively. The rate of complete aneurysm occlusion after a mean follow-up of 7.0 months was 66.0%.
CONCLUSIONS: The new FRED X is a safe and feasible device for aneurysm treatment. In this retrospective multicenter study, the rate of thrombotic complications was low, and the short-term occlusion rates are satisfactory.
引用
- Vollherbst DF, Lücking H, DuPlessis J, et al. The FRESH Study: Treatment of Intracranial Aneurysms with the New FRED X Flow Diverter with Antithrombotic Surface Treatment Technology-First Multicenter Experience in 161 Patients. AJNR Am J Neuroradiol. 2023. PMID: 36997283. doi:10.3174/ajnr.A7834
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。